DNA damage in blood leucocytes of prostate cancer patients during therapy with
Aged
Aged, 80 and over
DNA Breaks, Double-Stranded
DNA Damage
Dipeptides
/ administration & dosage
Dose-Response Relationship, Radiation
Heterocyclic Compounds, 1-Ring
/ administration & dosage
Humans
Leukocytes
/ radiation effects
Lutetium
Male
Middle Aged
Prostate-Specific Antigen
Prostatic Neoplasms
/ blood
Radiopharmaceuticals
/ administration & dosage
Radiotherapy Dosage
177Lu-PSMA
53BP1
Absorbed dose to the blood
Biodosimetry
DNA double-strand breaks
Prostate cancer
γ-H2AX
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
23
11
2018
accepted:
22
03
2019
pubmed:
28
4
2019
medline:
9
7
2020
entrez:
28
4
2019
Statut:
ppublish
Résumé
The aim of this study was to investigate the time- and dose-dependency of DNA double-strand break (DSB) induction and repair in peripheral blood leucocytes of prostate cancer patients during therapy with Blood samples from 16 prostate cancer patients receiving their first The average number of radiation-induced foci (RIF) per cell increased within the first 4 h after administration, followed by a decrease indicating DNA repair. The number of RIF during the first 2.6 h correlated linearly with the absorbed dose to the blood (R The general pattern of the time- and dose-dependent induction and disappearance of RIF during
Identifiants
pubmed: 31028426
doi: 10.1007/s00259-019-04317-4
pii: 10.1007/s00259-019-04317-4
pmc: PMC6584247
doi:
Substances chimiques
177Lu-PSMA-617
0
Dipeptides
0
Heterocyclic Compounds, 1-Ring
0
Radiopharmaceuticals
0
Lutetium
5H0DOZ21UJ
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1723-1732Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : LA 2304/3-2
Organisme : Deutsche Forschungsgemeinschaft
ID : SCHE 350/12-2
Références
J Cell Biol. 1999 Sep 6;146(5):905-16
pubmed: 10477747
J Cell Biol. 2000 Dec 25;151(7):1381-90
pubmed: 11134068
Mutat Res. 2002 Jan 15;513(1-2):27-36
pubmed: 11719087
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5057-62
pubmed: 12679524
J Cell Biochem. 2004 Feb 15;91(3):528-39
pubmed: 14755683
Mol Cell. 2005 Dec 9;20(5):801-9
pubmed: 16310392
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
J Nucl Med. 2010 Aug;51(8):1318-25
pubmed: 20660387
Ann Nucl Med. 2013 Apr;27(3):233-8
pubmed: 23264066
Radiat Res. 2013 Dec;180(6):603-9
pubmed: 24219325
PLoS One. 2014 Feb 03;9(2):e87458
pubmed: 24498326
J Nucl Med. 2015 Apr;56(4):505-11
pubmed: 25722453
PLoS One. 2015 Apr 08;10(4):e0123174
pubmed: 25853575
Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1739-1749
pubmed: 26048612
EJNMMI Res. 2015 Dec;5(1):114
pubmed: 26099227
J Nucl Med. 2016 Feb;57(2):173-9
pubmed: 26564321
J Nucl Med. 2016 Jul;57(7):1006-13
pubmed: 26795286
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
J Nucl Med. 2016 Aug;57(8):1170-6
pubmed: 26985056
J Nucl Med. 2016 Oct;57(Suppl 3):97S-104S
pubmed: 27694180
J Nucl Med. 2017 Jan;58(1):85-90
pubmed: 27765862
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
J Biol Chem. 1998 Mar 6;273(10):5858-68
pubmed: 9488723
Urology. 1998 Oct;52(4):637-40
pubmed: 9763084